The two-year rodent bioassay is one of several tests that are widely used by governmental regulatory agencies as well as pharmaceutical and chemical companies to determine the carcinogenic potential of chemicals or environmental agents where human exposure is anticipated. That this assay has remained relatively unchanged for the last 25 years is a testament to the power of this approach to identify carcinogens and thus to minimize human exposure. However, there has long been controversy over the specificity and relevance of the rodent bioassay as well as its high cost in terms of time, expense, and numbers of mice. Much discussion has been generated in recent years over how to improve the 2-year rodent bioassay for more accurate and faster detection of potential human carcinogens. Here, we argue that the use of p27Kip1 (Cdkn1b) knockout mouse for carcinogen screening may solve several shortcomings inherent in the conventional bioassay while preserving its best quality, that is, protecting public health by providing reliable in vivo information on the potential of chemicals to cause cancer.
Blanchard KT , Ball DJ, Holden HE, Furst SM, Stoltz JH, Stoll RE (1998). Dermal carcinogenicity in transgenic mice: Relative responsiveness of male and female hemizygous and homozygous Tg.AC mice to 12-O-tetradecanoylphorbol 13-acetate (TPA) and benzene. Toxicol Pathol26: 541—547.
2.
Cannon RE, Spalding JW, Trempus CS, Szczesniak CJ, Virgil KM, Humble MC, Tennant RW (1997). Kinetics of wound-induced v-Ha-ras transgene expression and papilloma development in transgenic Tg.AC mice. Mol Carcinog20: 108—114.
3.
Cannon RE, Spalding JW, Virgil KM, Faircloth RS, Humble MC, Lacks GD, Tennant RW (1998). Induction of transgene expression in Tg.AC(v-Ha-ras) transgenic mice concomitant with DNA hypomethylation. Mol Carcinog21: 244—250.
4.
Catzavelos C. , Bhattacharya N., Ung YC, Wilson JA, Roncari L., Sandhu C., Shaw P., Yeger H., Morava-Protzner I., Kapusta L., Franssen E., Pritchard KI, Slingerland JM (1997). Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer [see comments] . Nature Medicine3: 227—230.
5.
Cheng T., Rodrigues N., Dombkowski D., Stier S., Scadden DT (2000). Stem cell repopulation efficiency but not pool size is governed by p27(kip1). Nat Med6: 1235—1240.
6.
Chiarle R., Budel LM, Skolnik J., Frizzera G., Chilosi M., Corato A., Pizzolo G., Magidson J., Montagnoli A., Pagano M., Maes B., Wolf-Peeters C., Inghirami G. (2000). Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood95: 619—626.
7.
Ciaparrone M. , Yamamoto H., Yao Y., Sgambato A., Cattoretti G., Tomita N., Monden T., Rotterdam H., Weinstein IB (1998). Localization and expression of p27KIP1 in multistage colorectal carcinogenesis . Cancer Res58: 114— 122.
8.
Cohen SM (2001). Alternative models for carcinogenicity testing: Weight of evidence evaluations across models. Toxicol Pathol29(Suppl): 183—190.
9.
Cote RJ, Shi Y., Groshen S., Feng AC, Cordon-Cardo C., Skinner D., Lieskovosky G. (1998). Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst90: 916—920.
10.
Del Pizzo JJ , Borkowski A., Jacobs SC, Kyprianou N. (1999). Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival . Am J Pathol155: 1129—1136.
11.
Delker DA, Yano BL, Gollapudi BB (1999). V-Ha-ras gene expression in liver and kidney of transgenic Tg.AC mice following chemically induced tissue injury. Toxicol Sci50: 90—97.
12.
Deschenes C. , Vezina A., Beaulieu JF, Rivard N. (2001). Role of p27(Kip1) in human intestinal cell differentiation. Gastroenterology120: 423— 438.
13.
Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., Pandolfi PP (2001). Pten and p27Kip1 cooperate in prostate cancer tumor suppression in the mouse . Nat Genet27: 222—224.
14.
Erlanson M. , Portin C., Linderholm B., Lindh J., Roos G., Landberg G. (1998). Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood92: 770—777.
15.
Esposito V. , Baldi A., De Luca A., Groger AM, Loda M., Giordano GG, Caputi M., Baldi F., Pagano M., Giordano A. (1997). Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res57: 3381—3385.
16.
Farnsworth CL, Marshall MS, Gibbs JB, Stacey DW, Feig LA (1991). Preferential inhibition of the oncogenic form of rasH by mutations in the GAP binding/“effector” domain. Cell64: 625—633.
17.
Fero ML, Randel E., Gurley KE, Roberts JM, Kemp CJ ( 1998). The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature396: 177—180.
18.
Fero ML, Rivkin M., Tasch M., Porter P., Carow CE, Firpo E., Polyak K., Tsai LH, Broudy V., Perlmutter RM, Kaushansky K., Roberts JM (1996). A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27-deficient mice. Cell85: 733—744.
19.
Finch GL, March TH, Hahn FF, Barr EB, Belinsky SA, Hoover MD, Lechner JF, Nikula KJ, Hobbs CH (1998). Carcinogenic responses of transgenic heterozygous p53 knockout mice to inhaled 239PuO2 or metallic beryllium. Toxicol Pathol26: 484—491.
20.
Franklin DS , Godfrey VL, Lee H., Kovalev GI, Schoonhoven R., Chen-Kiang S., Su L., Xiong Y. (1998). CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev12: 2899—2911.
21.
Fredersdorf S., Burns J., Milne AM, Packham G., Fallis L., Gillett CE, Royds JA, Peston D., Hall PA, Hanby AM, Barnes DM, Shousha, S., O'Hare MJ, Lu X. (1997). High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA94: 6380—6385.
22.
French J., Storer RD, Donehower LA (2001). The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol Pathol29(Suppl): 24—29.
23.
Gulezian D. , Jacobson-Kram D., McCullough CB, Olson H., Recio L., Robinson D., Storer R., Tennant R., Ward JM, Neumann DA (2000). Use of transgenic animals for carcinogenicity testing: Considerations and implications for risk assessment . Toxicol Pathol28: 482—499.
24.
Gunther K., Jung A., Volker U., Meyer M., Brabletz T., Matzel KE, Reymond MA, Kirchner T., Hohenberger W. (2000). p27(kip1) expression in rectal cancer correlates with disease-free survival. J Surg Res92: 78— 84.
25.
Hengst L., Dulic V., Slingerland JM, Lees E., Reed SI ( 1994). A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA91: 5291—5295.
26.
Holden HE, Stoll RE, Spalding JW, Tennant RW (1998). Hemizygous Tg.AC transgenic mouse as a potential alternative to the two-year mouse carcinogenicity bioassay: Evaluation of husbandry and housing factors. J Appl Toxicol18: 19—24.
27.
Honchel R., Rosenzweig BA, Thompson KL, Blanchard KT, Furst SM, Stoll RE, Sistare FD (2001). Loss of palindromic symmetry in Tg.AC mice with a nonresponder phenotype. Mol Carcinog30: 99—110.
28.
Kim DH, Lee HI, Nam ES, Shin HS, Sohn JH, Park CH, Yoon DS, Song SY, Park YE ( 2000). Reduced expression of the cell-cycle inhibitor p27Kip1 is associated with progression and lymph node metastasis of gastric carcinoma . Histopathology36: 245—251.
29.
Korkolopoulou P., Christodoulou P., Konstantinidou AE, Thomas-Tsagli E., Kapralos P., Davaris P. (2000). Cell cycle regulators in bladder cancer: A multivariate survival study with emphasis on p27Kip1. Hum Pathol31: 751—760.
30.
Kwon OJ, Kang HS, Suh JS, Chang MS, Jang JJ, Chung JK (1999). The loss of p27 protein has an independent prognostic significance in gastric cancer. Anticancer Res19: 4215—4220.
31.
Leder A., Kuo A., Cardiff RD, Sinn E., Leder P. (1990). v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: Effects of phorbol esters and retinoic acid. Proc Natl Acad Sci USA87: 9178—9182.
32.
Levkau B., Koyama H., Raines EW, Clurman BE, Herren B., Orth K., Roberts JM, Ross R. ( 1998). Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: Role of a caspase cascade. MolecularCell1: 553—563.
33.
Liu DF, Ferguson K., Cooper GS, Grady WM, Willis J. (1999). p27 cell-cycle inhibitor is inversely correlated with lymph node metastases in right-sided colon cancer. J Clin Lab Anal13: 291—295.
34.
Loda M., Cukor B., Tam SW, Lavin P., Fiorentino M., Draetta, GF, Jessup JM, Pagano M. (1997). Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas . Nature Medicine3: 231—234.
35.
Mahler JF, Flagler ND, Malarkey DE, Mann PC, Haseman JK, Eastin W. (1998). Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicol Pathol26: 501—511.
36.
Maron DM, Ames BN ( 1983). Revised methods for the Salmonella mutagenicity test . Mutat Res113: 173—215.
37.
Maronpot RR , Boorman GA (1996). The contribution ofthe mouse in hazard identification studies. Toxicol Pathol24: 726—731.
38.
Masciullo V. , Sgambato A., Pacilio C., Pucci B., Ferrandina G., Palazzo J., Carbone A., Cittadini A., Mancuso S., Scambia G., Giordano A. (1999). Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer . Cancer Res59: 3790—3794.
39.
Mori M., Mimori K., Shiraishi T., Tanaka S., Ueo H., Sugimachi K., Akiyoshi T. (1997). p27 expression and gastric carcinoma. Nature Medicine3: 593.
40.
Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., Loh D. (1996). Mice lacking p27 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell85: 707—720.
41.
NationalToxicology Program . 10th Report on Carcinogens. 10. 12-17-2002. 〈http://ehp.niehs.nih.gov/roc/toc10.html〉, National Institute of Environmental Health Sciences. Ref Type: Report.
42.
Newcomb EW, Sosnow M., Demopoulos RI, Zeleniuch-Jacquotte A., Sorich J., Speyer JL (1999). Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol154: 119—125.
43.
Osawa H., Shitara Y., Shoji H., Mogi A., Kuwano H., Hagiwara K., Takenoshita S. (2000). Mutation analysis of transforming growth factor beta type II receptor, Smad2, Smad3 and Smad4 in esophageal squamous cell carcinoma. Int J Oncol17: 723—728.
44.
Oshita F., Kameda Y., Nishio K., Tanaka G., Yamada K., Nomura I., Nakayama H., Noda K. ( 2000). Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer. Oncol Rep7: 491—495.
45.
Palmqvist R. , Stenling R., Oberg A., Landberg G. (1999). Prognostic significance of p27(Kip1) expression in colorectal cancer: A clinico-pathological characterization . J Pathol188: 18—23.
46.
Park MS, Rosai J., Nguyen HT, Capodieci P., Cordon-Cardo C., KoffA (1999). p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci USA96: 6382—6387.
47.
Pettit SD (2001). Panel discussion on the application of alternative models to cancer risk assessment. Toxicol Pathol29(Suppl): 191—195.
48.
Philipp J., Vo K., Gurley KE, Seidel K., Kemp CJ ( 1999). Tumor suppression by p27/Kip1 and p21/Cip1 during chemically induced skin carcinogenesis. Oncogene18: 4689—4698.
49.
Philipp-Staheli J., Kim KH, Payne SR, Gurley KE, Liggitt D., Longton G., Kemp CJ (2002). Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice. CancerCell1: 355—368.
50.
Philipp-Staheli J., Payne SR, Kemp CJ (2001). p27(Kip1): Regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res264: 148—168.
51.
Polyak K., Lee MH, Erdjument-Bromage H., Koff A., Roberts JM, Tempst P., Massague J. (1994). Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals . Cell78: 59— 66.
52.
Popp JA (2001). Criteria for the evaluation of studies in transgenic models. Toxicol Pathol29(Suppl): 20—23.
53.
Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM (1997). Expression of cell-cycle regulators p27 Kip-1 and cyclin E alone and in combination, correlate with survival in young breast cancer patients. Nature Medicine3: 222—225.
54.
Robinson DE , MacDonald JS (2001). Background andframeworkfor ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute. Toxicol Pathol29(Suppl): 13—19.
55.
Saitoh A., Kimura M., Takahashi R-I., Yokoyama M., Nomura T., Izawa M., Sekiya T., Nishimura S., Katsuki M. (1990). Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene5: 1195—1200.
56.
Sgambato A. , Cittadini A., Faraglia B., Weinstein IB (2000). Multiple functions of p27(Kip1) and its alterations in tumor cells: A review . J Cell Physiol183: 18—27.
57.
Sgambato A. , Ratto C., Faraglia B., Merico M., Ardito R., Schinzari G., Romano G., Cittadini AR (1999). Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer. Mol Carcinog26: 172—179.
58.
Shamma A., Doki Y., Tsujinaka T., Shiozaki H., Inoue M., Yano M., Kawanishi K., Monden M. (2000). Loss ofp27(KIP1) expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Oncology58: 152— 158.
59.
Sherr CJ, Roberts JM (1995). Inhibitors of mammalian G1 cyclin-dependent kinases . Genes Dev9: 1149—1163.
60.
Sherr CJ, Roberts JM (1999). CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev13: 1501—1512.
61.
Singh SP, Lipman J., Goldman H., Ellis FH, Jr, Aizenman L., Cangi MG, Signoretti S., Chiaur DS, Pagano M., Loda M. ( 1998). Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res58: 1730—1735.
62.
Slingerland J., Pagano M. (2000). Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol183: 10—17.
63.
Spalding JW , French JE, Tice RR, Furedi-Machacek M., Haseman JK, Tennant RW (1999). Development of a transgenic mouse model for carcinogenesis bioassays: Evaluation of chemically induced skin tumors in Tg.AC mice. Toxicol Sci49: 241—254.
64.
Spalding JW , Momma J., Elwell MR, Tennant RW (1993). Chemically induced skin carcinogenesis in a transgenic mouse line (TG-AC) carrying a v-Ha-ras gene . Carcinogenesis14: 1335—1341.
65.
Tamaoki N. (2001). The rasH2 transgenic mouse: Nature of the model and mechanistic studies on tumorigenesis. Toxicol Pathol29(Suppl): 81—89.
66.
Tan P., Cady B., Wanner M., Worland P., Cukor B., Magi-Galluzzi C., Lavin P., Draetta G., Pagano M., Loda M. ( 1997). The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res57: 1259—1263.
Tennant RW, Spalding J., French JE (1996). Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat Res365: 119—127.
69.
Tennant RW, Stasiewicz S., Eastin WC, Mennear JH, Spalding JW (2001). The Tg.AC (v-Ha-ras) transgenic mouse: Nature of the model. Toxicol Pathol29(Suppl): 51—59.
70.
Thomas GV, Szigeti K., Murphy M., Draetta G., Pagano M., Loda M. ( 1998). Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol153: 681—687.
71.
Thompson KL , Rosenzweig BA, Sistare FD (1998). An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness. Toxicol Pathol26: 548—555.
72.
Trempus CS, Mahler JF, Ananthaswamy HN, Loughlin SM, French JE, Tennant RW (1998). Photocarcinogenesis and susceptibility to UV radiation in the v-Ha-ras transgenic Tg.AC mouse. J Invest Dermatol111: 445— 451.
73.
Tsihlias J. , Kapusta LR, DeBoer G., Morava-Protzner I., Zbieranowski I., Bhattacharya N., Catzavelos GC, Klotz LH, Slingerland JM (1998). Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res58: 542—548.
74.
Tsihlias J. , Kapusta L., Slingerland J. (1999). The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med50: 401—423.
75.
van Steeg H. , de Vries A., van Oostrom CT, van Benthem J., Beems RB, Van Kreijl CF (2001). DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: Nature of the models . Toxicol Pathol29(Suppl): 109—116.
76.
Wang D., Kanuma T., Takama F., Mizumuma H., Ibuki Y., Wake N., Mogi A., Shitara Y., Hagiwara K., Takenoshita S. (1999). Mutation analysis of the Smad3 gene in human ovarian cancers. Int J Oncol15: 949—953.
77.
Weaver JL, Contrera JF, Rosenzweig BA, Thompson KL, Faustino PJ, Strong JM, Ellison CD, Anderson LW, Prasanna HR, Long-Bradley PE, Lin KK, Zhang J., Sistare FD (1998). An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype. Toxicol Pathol26: 532—540.
78.
Xiangming C. , Natsugoe S., Takao S., Hokita S., Tanabe G., Baba M., Kuroshima K., Aikou T. (2000). The cooperative role of p27 with cyclin E in the prognosis of advanced gastric carcinoma. Cancer89: 1214— 1219.
79.
Yamamoto S., Urano K., Koizumi H., Wakana S., Hioki K., Mitsumori K., Kurokawa Y., Hayashi Y., Nomura T. (1998). Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing . Environ Health Perspect106(Suppl) 1: 57— 69.
80.
Yang RM, Naitoh J., Murphy M., Wang HJ, Phillipson J., deKernion JB, Loda M., Reiter RE (1998). Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urology159: 941— 945.
81.
Yasui W., Kudo Y., Semba S., Yokozaki H., Tahara E. (1997). Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res88: 625—629.
82.
Yatabe Y., Masuda A., Koshikawa T., Nakamura S., Kuroishi T., Osada H., Takahashi T., Mitsudomi T. (1998). p27KIP1 in human lung cancers: Differential changes in small cell and non-small cell carcinomas. Cancer Res58: 1042—1047.
83.
Zeiger E. (1987). Carcinogenicity of mutagens: Predictive capability of the Salmonella mutagenesis assay for rodent carcinogenicity. Cancer Res47: 1287—1296.
